Guggenheim Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Dianthus Therapeutics (NASDAQ:DNTH) had its price target lifted by Guggenheim from $92.00 to $100.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on DNTH. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday. Wedbush boosted their price target on Dianthus Therapeutics from $34.00 to $42.00 and gave the company an “outperform” rating in a research note on Thursday, August 21st. William Blair initiated coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an “outperform” rating for the company. Finally, Robert W. Baird boosted their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $60.67.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $35.57 on Tuesday. The firm has a 50-day moving average of $21.89 and a 200-day moving average of $20.20. The stock has a market cap of $1.14 billion, a PE ratio of -10.94 and a beta of 1.46. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $36.57.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Equities research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics in the second quarter worth about $27,000. US Bancorp DE lifted its holdings in shares of Dianthus Therapeutics by 2,013.3% in the first quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after acquiring an additional 1,510 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $59,000. GAMMA Investing LLC lifted its holdings in shares of Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock worth $70,000 after acquiring an additional 3,758 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.